Adverse Drug Reaction (ADR) Monitoring Centre (AMC) MPMMCC Varanasi, under PvPI, IPC, MoHFW, Govt of India.
AMC MPMMCC Varanasi is the recipient of the PvPI Patient Safety Excellence Award 2025 (IPC, Govt of India).
Select one or more reaction terms. SOC shown as abbr + full text.
Use this only if you cannot find a matching term in the dictionary search.
OUTPUT (TXT) — use these buttons
(Click “Build TXT Preview”)
ADR reporting note:
1) Reporting an ADR is not a legal accusation.
2) It does not blame the manufacturer, distributor, seller, hospital, or any healthcare worker.
3) This is a patient-safety signal for pharmacovigilance.
4) The reporter is not required to prove that the drug caused the event.
5) Causality assessment will be done later by the AMC using standard methods and available clinical records.
MedDRA is not bundled. Import PT list if you have a licensed copy / authorised access.
XLSX is not parsed in this offline build. ICQT (EMA IME v28.1) is already embedded. For XLSX imports, first convert to CSV/TSV and then import.
Point-of-Care Causality (Advanced, for AMC use)
These tools assist structured documentation. They do not replace clinical judgment. Use alongside records (CIS/EMR) when doing formal AMC causality assessment.
The Naranjo Algorithm (10-question probability scale)
Select exactly one option per question.
1) Are there previous conclusive reports on this reaction?
2) Did the adverse event appear after the suspected drug was administered?
3) Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered?
4) Did the adverse reaction reappear when the drug was re-administered?
5) Are there alternative causes that could have caused the reaction?
6) Did the reaction reappear when a placebo was given?
7) Was the drug detected in the blood (or other fluids) in concentrations known to be toxic?
8) Was the reaction more severe when the dose was increased, or less severe when the dose was decreased?
9) Did the patient have a similar reaction to the same or similar drugs in any previous exposure?
10) Was the adverse event confirmed by any objective evidence?